Alex Bastian Named VP of Commercial Strategy at Memo Therapeutics
Alex Bastian Joins Memo Therapeutics AG as VP of Commercial Strategy
Memo Therapeutics AG (or “MTx”), a late-stage biotech company dedicated to translating unique human immune responses into superior medicines designed to treat viral infections and cancer, has announced the appointment of Alex Bastian as the new VP of Commercial Strategy.
Expertise in the Biotech Sector
Alex Bastian brings a wealth of experience as a seasoned commercial leader within the biotech industry. His most recent position was at AM-Pharma, where he served as the VP of Commercial & Patient Access and was instrumental in leading market access initiatives for an innovative therapy aimed at treating acute kidney injury.
Previous Experience
Before his time at AM-Pharma, Alex held the position of VP and Head of Value & Market Access at Galapagos. In this role, he was key in establishing a global function for market access, health economics, and policy, successfully launching a product in a very competitive therapy area. His extensive career spans multiple senior roles at major pharmaceutical firms, including Incyte Consulting, with experience in both European and U.S. markets.
Company’s Growth and Future Opportunities
Erik van den Berg, CEO of MTx, expressed his enthusiasm about Alex's joining the company, especially as they approach the launch of a Phase III trial focused on kidney transplant patients suffering from BK virus infections. This upcoming trial marks a significant step towards commercial launch, and the addition of Alex enhances MTx's internal capabilities at a pivotal time.
Innovation in Treatment Options
Alex Bastian stated, “With a best and first-in-class antibody for BK viremia, MTx offers new hope for patients who currently lack effective treatment alternatives. I am excited to join a company with such an innovative asset and a strong technology platform, and I eagerly anticipate collaborating with the talented team at MTx.”
Educational Background and Recent Funding
Currently, Alex is finalizing a Doctor of Public Health degree at the prestigious Johns Hopkins Bloomberg School of Public Health and holds an MBA from IESE Business School in Barcelona, along with a Bachelor of Arts degree from the University of Minnesota.
Recently, Memo Therapeutics AG announced a successful funding round, raising an additional CHF 20 million, amid new investments from Ysios Capital and Kurma Partners. This brings the total Series C funding to CHF 45 million. Earlier in the summer, MTx publicized the appointment of Paul Carter as the Chairperson of the Board of Directors, a role for which he brings over a decade of commercial expertise in the virology sector, particularly from his time at Gilead Sciences.
About Memo Therapeutics AG
Memo Therapeutics AG is at the forefront of biotechnological development, actively working on unique approaches to combat viral infections and cancer through cutting-edge therapies. Their lead product, Potravitug, currently in Phase II development, is targeting BK viremia among kidney transplant patients—a crucial innovation addressing significant health challenges and aiming for a market potential exceeding $1 billion.
The company's commitment extends beyond Potravitug; it is also pursuing novel oncology targets and fostering partnerships to enhance its offerings, having established a significant partnership with Ono Pharmaceutical since late 2022. MTx's proprietary DROPZYLLA technology serves as the backbone of their core assets, facilitating the high-throughput screening of antibody repertoires.
As a private entity situated in Schlieren / Zurich, the company is backed by an array of investors, including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital, and Adjuvant Capital.
Frequently Asked Questions
What role has Alex Bastian taken on at Memo Therapeutics AG?
Alex Bastian has been appointed as the VP of Commercial Strategy at Memo Therapeutics AG.
What is the main focus of Memo Therapeutics AG?
Memo Therapeutics AG is focused on developing innovative treatments for viral infections and cancer, specifically through their lead program, Potravitug.
What is Potravitug?
Potravitug is an antibody therapy currently in Phase II development aimed at treating BK viremia in kidney transplant recipients.
Who is the CEO of Memo Therapeutics AG?
Erik van den Berg is the CEO of Memo Therapeutics AG.
How much funding has Memo Therapeutics AG recently secured?
Memo Therapeutics AG recently secured an additional CHF 20 million, bringing their total Series C financing to CHF 45 million.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Calumet Secures Strategic Partnership with Stonebriar Finance
- VF Corp Finalizes Major Sale, Impacts Future Strategies
- Devon Energy's Major Resale of Common Stock Following Acquisition
- Hyperscale Data's Strategic $13.2M Property Sale Explained
- Changes in Leadership at ON Semiconductor Amid Growth Surge
- Virpax Pharmaceuticals Welcomes Katharyn Field as VP
- Biden Urges Immediate Aid for Hurricane Helene Victims Now
- EVgo and Trump Media: Latest Post-Market Stock Reactions
- Constellation Brands Showcases Strong Beer Growth Amid Challenges
- Charles River Showcases Innovations at Neuroscience 2024 Event
Recent Articles
- Oxford Biomedica's Free Webinar on AAV Expertise
- Challenges Facing Medical Properties Trust (NYSE: MPW)
- Advancements in Internal Combustion Engine Technology
- Continuous Learning - The Role of Ongoing Education in Business Innovation
- Steakholder Foods Announces Participation in Investment Conference
- EnerPure Reports 51% IRR Increase for UMO Recycling Plant
- Chevron's Strategic Acquisition of Hess: What to Expect
- Contactless Payments Market Growth and Dynamics
- Polyurethane Coating Market: A Game-Changer in Surface Protection
- Paramount Gold Advances Grassy Mountain Gold Mine Permits
- Wood Preservatives Market Growth Insights and Future Trends
- Compact Wheel Loader Market to Reach US$ 66.83 Billion
- DSV A/S Announces Share Buyback Programme Details
- Intermap Partners with Aon to Enhance Insurance Solutions
- InflaRx to Showcase Innovations at Upcoming Investor Events
- COSCIENS Biopharma's DETECT-Trial Reveals Surprising Results
- ProKidney to Attend Major Healthcare Conference
- Fancamp Partners with Lode Gold to Enhance Mineral Assets
- Avicanna Secures Patent for Innovative Topical Cannabinoid Technology
- Cartier Resources Reports High-Grade Gold Intersections
- Abcourt Mines Reports High-Grade Gold Intersections
- Bread Financial™ to Engage at Barclays Financial Services Conference
- CERIS Innovations in Fraud Prevention Solutions
- Archrock Completes HSR Act Waiting Period for Acquisition
- SEALSQ Corp Innovations in Quantum-Resistant Digital Wallets
- Investing Insights into Berkshire Hathaway's Performance
- Investing in Current Stock Market Giants
- Ozempic's Impact on Novo Nordisk: Recent Findings
- Mural Oncology to Join Major Investor Conferences
- European Wax Center to Speak at Piper Sandler Conference
- EyePoint Pharmaceuticals Prepares for Investor Conferences
- Super Hi Reports Strong Q2 2024 Financial Results
- Invivyd's PEMGARDA™ Shows 84% Risk Reduction in COVID-19
- Supremex Launches First Environmental, Social and Governance Report
- Fox Factory's Commitment to Sustainability in 2023
- Clearside Biomedical Completes Final Participant Visit in ODYSSEY Trial
- Advancements in the Cosmetic Peptide Synthesis Market
- Vacuum Evaporation Boat Market Expected Growth to $4.1 Billion
- Skydance Media to Acquire Paramount Global Amid Bidding War
- Solar Coca-Cola Boosts Delivery Efficiency with Descartes
- Palo Alto Networks: AI and Cybersecurity Leadership
- Alliance Trust PLC Reports Latest Net Asset Value Insights
- Scotiabank Reports Drop in Q3 Profit Amid Credit Loss Provisions
- Iovance Biotherapeutics: A Path to Growth with Amtagvi
- Market Update: Investors Eye Nvidia's Earnings
- Aircraft Ground Support Equipment Market Growth Insights
- 3D Printing Glasses Market Growth Forecast
- Underground Mining Equipment Market Growth Forecast
- Laser Gas Analyzer Market Set to Reach $5.39 Billion by 2034
- Cheer Holding Secures Patent for AI Data Management System